4314-68-5

Basic information

• Product Name: 3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID
• Synonyms: P-METHOXY-A-PHENYLHYDROCINNAMIC ACID;3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID;3-(P-METHOXYPHENYL)-2-PHENYLPROPIONIC ACID;3-(4-methoxyphenyl)-2-phenylpropanoic acid;4-Methoxy-α-phenylbenzenepropanoic acid;Einecs 224-332-2;Benzenepropanoic acid, 4-Methoxy-α-phenyl-
• CAS NO: 4314-68-5
• Molecular Formula: C₁₆H₁₆O₃
• Molecular Weight: 256.3
• EINECS: 224-332-2
• Mol File: 4314-68-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 381.2 °C at 760 mmHg
• Flash Point: 138 °C
• Appearance: /
• Density: 1.171 g/cm³
• Vapor Pressure: 1.72E-06mmHg at 25°C
• CAS DataBase Reference: 3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID(4314-68-5)
• EPA Substance Registry System: 3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID(4314-68-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 4314-68-5(Hazardous Substances Data)

Usage

General Description

3-(4-Methoxy-phenyl)-2-phenyl-propionic acid, also known as flurbiprofen, is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and inflammation in conditions such as arthritis, menstrual cramps, and musculoskeletal injuries. It works by inhibiting the production of cyclooxygenase enzymes, which are responsible for the synthesis of prostaglandins that cause pain and inflammation. Flurbiprofen is available as both prescription and over-the-counter medication and is often taken orally in the form of tablets or capsules. It is generally well-tolerated, but may cause side effects such as stomach irritation, headache, and dizziness in some individuals. Due to its anti-inflammatory and analgesic properties, flurbiprofen is widely used in the medical treatment of various pain-related ailments.

InChI:InChI=1/C16H16O3/c1-19-14-9-7-12(8-10-14)11-15(16(17)18)13-5-3-2-4-6-13/h2-10,15H,11H2,1H3,(H,17,18)/p-1/t15-/m1/s1

Upstream product

• 6968-77-0 3-(4-methoxyphenyl)-2-phenylacrylic acid 
• 103-82-2 phenylacetic acid 
• 824-94-2 p-methoxybenzyl chloride 
• 1262329-30-5 C₁₆H₁₃ClO₃ 
• 2177-74-4 (2E)-2-(4-chlorophenyl)-3-(4-methoxyphenyl)prop-2-enoic acid 
• 5448-41-9 methyl 3-(4'-methoxyphenyl)-2-phenylpropanoate 
• 2746-25-0 p-Methoxybenzyl bromide 
• 101-41-7 benzeneacetic acid methyl ester 
• 6968-77-0 2-phenyl-3-p-methoxyphenylacrylic acid 

Downstream Products

• 5448-41-9 methyl 3-(4'-methoxyphenyl)-2-phenylpropanoate 
• 108840-75-1 6-methoxy-2-phenylindan-1-one 
• 89-23-6 3-(4-hydroxyphenyl)-2-phenylpropanoic acid 
• 106319-23-7 (2R)-3-(4-methoxyphenyl)-2-phenylpropanoic acid 
• 577-91-3 3-(4-hydroxy-3,5-diiodo-phenyl)-2-phenyl-propionic acid 
• 5189-39-9 2-Phenyl-3--6-methoxyinden-3-¹⁴C 
• 116132-52-6 (1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-(4-methoxyphenyl)-2-phenylpropanoate 
• 1538615-09-6 ethyl 3-(4-methoxyphenyl)-2-methyl-2-phenylpropanoate 
• 875231-52-0 3-(4-methoxyphenyl)-2-methyl-2-phenylpropanoic acid 
• 109250-59-1 ethyl 3-(4-methoxyphenyl)-2-phenylpropanoate 
• 57151-38-9 1-amino-2-(p-methoxyphenyl)-1-phenylethane 
• 80654-78-0 1-{6,7-Dimethoxy-1-[2-(4-methoxy-phenyl)-1-phenyl-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-ethanone 
• 80654-75-7 2-Ethyl-6,7-dimethoxy-1-[2-(4-methoxy-phenyl)-1-phenyl-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 80654-63-3 N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-3-(4-methoxy-phenyl)-2-phenyl-propionamide 

Relevant articles and documents

AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS

The present invention provides in one aspect azabicycio and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulae (I) & (II):

Reactions of chlorine substituted (E)-2,3-diphenylpropenoic acids over cinchonidine-modified Pd: Enantioselective hydrogenation versus hydrodechlorination

The effect of the chlorine position on the C-Cl bond hydrogenolysis and the enantioselective hydrogenation of Cl substituted (E)-2,3-diphenylpropenoic acid derivatives has been studied over cinchonidine-modified Pd/Al2O 3. In contrast to the fast hydrodechlorination of the β-phenyl-para-Cl substituted acids the Cl on the α-phenyl ring was barely hydrogenolized. These observations were interpreted by the different arrangements of the two phenyl rings on the surface, with the α- and β-phenyl rings adsorbed tilted and parallel, respectively. The results confirmed the beneficial effect of the α-phenyl-ortho-substituents on the chiral discrimination, thus the 2,3-diphenylpropionic acids substituted by Cl on the α-phenyl ring could be prepared in good yields and optical purities. The conclusions were used for the rational design of an acid, i.e. (E)-2-(2-methoxyphenyl)-3-(3,4-difluorophenyl)propenoic acid, which afforded the best optical purity (ee up to 95% at 295 K) described until now in this heterogeneous system.

PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM

Therapeutically active compounds of formula (I) or (II) wherein X is -O-, -CH2- or -C(O)-; Z is -CHR12- or a valence bond; Y is -CH2-, -C(O)-, CH(OR13)-, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is -CR12- -and Y is -CH2-, -C(O)- or -CH(OR10)- (in formula II) or -CH- (in formula I); R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, benzyloxy or a group of formula (IIIa). R1 is H, CN, halogen, -CONH2, -COOR15, CH2NR15R18, NHC(O)R5, NHCH2R5, NHR20, NR21R22, NHC(NH)NHCH3 or, in case the compound is of formula (II) wherein the optional double bond exists or in case R2 or R3 is benzyloxy or a group of formula (IIIa) or in case the pyridine ring of formula (I) or (II) is attached to the oxygen atom in 3-, 4- or 5-position, R1 can also be -NO2 or NR16R17; R4 is H, -NO2, CN, halogen, -CONH2, -COOR15, -CH2NR15R18, -NR16R17, NHC(O)R5 or -NHC(NH)NHCH3; R5 is alkyl substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxy, or carboxyalkyl, in which the alkyl portion is optionally substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxyl, -CHR6NR,R8 or one of the following groups: formula (IVa), (IVb), (IVc), (IVd), (IVe), and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.